Amubarvimab, previously known as BI 196, represents a crucial advancement in biopharmaceutical development, particularly concerning its ability to inhibit COVID-19. This engineered agent demonstrates remarkable efficacy against new strains of the pathogen , showing promise for both prophylactic and therapeutic applications. Early patient findings s